Literature DB >> 19714790

More on bevacizumab in hereditary hemorrhagic telangiectasia.

Frederique Retornaz, Yves Rinaldi, Christophe Duvoux.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19714790

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.

Authors:  C Rohrmeier; H G Sachs; T S Kuehnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-31       Impact factor: 2.503

Review 2.  Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.

Authors:  Wanqiu Chen; Eun-Jung Choi; Cameron M McDougall; Hua Su
Journal:  Transl Stroke Res       Date:  2014-04-12       Impact factor: 6.829

3.  Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.

Authors:  Narendranath Epperla; William Hocking
Journal:  Clin Med Res       Date:  2014-03-25

Review 4.  Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.

Authors:  Daniela S Ardelean; Michelle Letarte
Journal:  Front Genet       Date:  2015-02-11       Impact factor: 4.599

5.  Intravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia, ENG E137K, Alcoholic Cirrhosis, and Portal Hypertension.

Authors:  Luigi F Bertoli; Pauline L Lee; Lauren Lallone; James C Barton
Journal:  Case Rep Gastroenterol       Date:  2017-05-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.